Roche joins the oral SERD club as FDA clears Wilserdly

News
Roche joins the oral SERD club as FDA clears Wilserdly

Roche is the latest drugmaker to bring an oral SERD drug for breast cancer to the US market, after getting FDA approval for Wilserdly, which the company calls a "next-generation" drug.

Wilserdly (giredestrant) has been cleared in combination with everolimus for previously treated patients with HR-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer, based on the results of the evERA trial.

Wilserdly is the fourth drug in the oral SERD class to be greenlit by the FDA, after AstraZeneca's Etcamah (camizestrant) – recently cleared for first-line use in this type of cancer – as well as Menarini/Stemline's Orserdu (elacestrant) and Eli Lilly's Inluriyo (imlunestrant), which are indicated for second-line use.

Wilserdly's specific indication is for patients whose disease has recurred during or after completion of endocrine-based adjuvant therapy, or has progressed on at least one endocrine-based regimen in the metastatic setting.

In a statement, Roche said Wilserdly/everolimus is the only oral SERD to outperform standard endocrine combination therapy in a post-CDK4/6 inhibitor setting in a head-to-head phase 3 trial.

The evERA trial – which was recently reported in The New England Journal of Medicine – showed that Wilserdly/everolimus significantly prolonged progression-free survival (PFS), achieving a 62% reduction in the risk of disease progression or death compared to standard endocrine therapy plus everolimus.

"For patients with ESR1-mutated advanced breast cancer, the development of resistance to endocrine therapy remains a substantial challenge – often requiring more intensive treatment," said Levi Garraway, Roche's chief medical officer.

"By pairing potent oestrogen receptor degradation with everolimus, Wilserdly offers a targeted, all-oral regimen that significantly delays disease progression and allows advanced breast cancer patients to take their treatment from home."

ESR1 mutations are thought to be the primary cause of hormone therapy resistance, affecting up to 40% of patients, according to Roche.

The company has also filed for approval of Wilserdly as an adjuvant (post-surgery) treatment for HR-positive, HER2-negative early breast cancer, based on the lidERA trial results, with a decision due by the end of this month. If the FDA clears that extension to the label, Roche will leapfrog its rivals in the early-stage setting.

Roche said it is preparing to launch Wilserdly in the US "almost immediately" and has set a list price for the drug of $22,500 per month, which is roughly in line with the other three oral SERDs on the market.